Narrow therapeutic window of ribavirin as an inhibitor of nitric oxide synthesis is broadened by macromolecular prodrugs

Biomacromolecules

Volumn 14, Issue 11, 2013, Pages 3916-3926

  Wohl, Benjamin M ^a   Smith, Anton A A ^a   Kryger, Mille B L ^a   Zelikin, Alexander N ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFLAMMATORY ACTIVITY; EXPERIMENTAL VALUES; INTER-DISCIPLINARY STUDIES; MECHANISM OF ACTION; N-VINYL PYRROLIDONE; POLYMER THERAPEUTICS; RAFT POLYMERIZATION; SYNTHESIZED POLYMERS;

AMIDES; ANTIVIRAL AGENTS; LIVING POLYMERIZATION; MACROMOLECULES; MACROPHAGES; NITRIC OXIDE; POLYDISPERSITY; VIRUSES;

FUNCTIONAL POLYMERS;

ACRYLIC ACID DERIVATIVE; ANTIINFLAMMATORY AGENT; NITRIC OXIDE; POLYMER; POVIDONE; PRODRUG; RIBAVIRIN; RIBAVIRIN ACRYLATE; RIBAVIRIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LEVEL; CELL STIMULATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RELEASE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MACROMOLECULE; MACROPHAGE; MOLECULAR WEIGHT; POLYMERIZATION; PRIORITY JOURNAL; REVERSIBLE ADDITION FRAGMENTATION CHAIN TRANSFER POLYMERIZATION;

ANIMALS; ANTIVIRAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HEP G2 CELLS; HUMANS; MACROMOLECULAR SUBSTANCES; MACROPHAGES; MICE; MOLECULAR STRUCTURE; NITRIC OXIDE; PRODRUGS; RIBAVIRIN; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 84887590759     PISSN: 15257797     EISSN: 15264602     Source Type: Journal    
DOI: 10.1021/bm401048s     Document Type: Article

References (62)

1. WHO. Hepatitis C, 2012; http://www.who.int/mediacentre/factsheets/fs164/ en/index.html.
2. Sharma, P.; Lok, A. Viral hepatitis and liver transplantation Semin. Liver Dis. 2006, 26 (3) 285-297
3. Dore, G. J.; Matthews, G. V.; Rockstroh, J. Future of hepatitis C therapy: Development of direct-acting antivirals Curr. Opin. HIV AIDS 2011, 6, 508-513
4. Tan, S.-L.; Pause, A.; Shi, Y.; Sonenberg, N. Hepatitis C therapeutics: Current status and emerging strategies Nat. Rev. Drug Discovery 2002, 1, 867-881
5. Fried, M. W.; Hadziyannis, S. J. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin Semin. Liver Dis. 2004, 24 (SUPPL. 2) 47-54
6. Fried, M. W. Side effects of therapy of hepatitis C and their management Hepatology 2002, 36 (5B) s237-s244
7. Brillanti, S.; Mazzella, G.; Roda, E. Ribavirin for chronic hepatitis C: And the mystery goes on Digest. Liver Dis. 2011, 43, 425-430
8. Sidwell, R. W.; Huffman, J. H.; Khare, L., G. P.; Allen, B.; Witkowski, R., J. T.; Robins, K. Broad-spectrum antiviral activity of virazole: 1-f8- d -Ribofuranosyl-1,2,4-triazole- 3-carboxamide Science 1972, 177 (4050) 705-706
9. Patterson, J. L.; Fernandez-Larsson, R. Molecular mechanisms of action of ribavirin Rev. Infect. Dis. 1990, 12 (6) 1139-1146
10. Jain, M. K.; Zoellner, C. Role of ribavirin in HCV treatment response: Now and in the future Expert Opin. Pharmacother. 2010, 11, 673-683
11. De Franceschi, L.; Fattovich, G.; Turrini, F.; Ayi, K.; Brugnara, C.; Manzato, F.; Noventa, F.; Stanzial, A. M.; Solero, P.; Corrocher, R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage Hepatology 2000, 31 (4) 997-1004
12. Canonico, P. G.; Kastello, M. D.; Spears, C. T.; Brown, J. R.; Jackson, E. A.; Jenkins, D. E. Effects of ribavirin on red blood cells Toxicol. Appl. Pharmacol. 1984, 74 (2) 155-162
13. Brochot, E.; Castelain, S.; Duverlie, G.; Capron, D.; Nguyen-Khac, E.; François, C. Ribavirin monitoring in chronic hepatitis C therapy: Anaemia versus efficacy Antiviral Ther. 2010, 15 (5) 687-695
14. Gilbert, B. E.; Knight, V. Biochemistry and clinical applications of ribavirin Antimicrob. Agents Chemother. 1986, 30 (2) 201-205
15. Naik, G. S.; Tyagi, M. G. A Pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection J. Clin. Exp. Hepatol. 2012, 2 (1) 42-54
16. Feld, J. J.; Hoofnagle, J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 2005, 436, 967-972
17. Hofmann, W. P.; Herrmann, E.; Sarrazin, C.; Zeuzem, S. Ribavirin mode of action in chronic hepatitis C: From clinical use back to molecular mechanisms Liver Int. 2008, 28, 1332-1343
18. De Clercq, E. Strategies in the design of antiviral drugs Nat. Rev. Drug Discovery 2002, 1, 13-25
19. Michaelis, M.; Michaelis, R.; Suhan, T.; Schmidt, H.; Mohamed, A.; Doerr, H. W.; Cinatl, J., Jr. Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion FASEB J. 2007, 21, 81-87
20. Marletta, M. A. Nitric oxide synthase structure and mechanism J. Biol. Chem. 1993, 268, 12231-12234
21. Streeter, D. G.; Witkowski, J. T.; Khare, G. P.; Sidwell, R. W.; Bauer, R. J.; Robins, R. K.; Simon, L. N. Mechanism of action of 1- d -ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent Proc. Natl. Acad. Sci. U.S.A. 1973, 70 (4) 1174-1178
22. Kast, R. E. Ribavirin in cancer immunotherapies: Controlling nitric oxide augments cytotoxic lymphocyte function Neoplasia 2003, 5, 3-8
23. Majano, P. L.; Garcia-Monzon, C. Does nitric oxide play a pathogenic role in hepatitis C virus infection? Cell Death Differ. 2003, 10, S13-S15
24. Allison, A. C. Mechanisms of action of mycophenolate mofetil Lupus 2005, 14, s2-s8
25. Kryger, M. B. L.; Wohl, B. M.; Smith, A. A. A.; Zelikin, A. N. Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug Chem. Commun. 2013, 49 (26) 2643-2645
26. Duncan, R. The dawning era of polymer therapeutics Nat. Rev. Drug Discovery 2003, 2 (5) 347-360
27. Li, W.; Chang, Y.; Zhan, P.; Zhang, N.; Liu, X.; Pannecouque, C.; De Clercq, E. Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3′-azido-3′- deoxythymidine (AZT, Zidovudine) ChemMedChem 2010, 5 (11) 1893-1898
28. Li, W. J.; Wu, J. D.; Zhan, P.; Chang, Y.; Pannecouque, C.; De Clercq, E.; Liu, X. Y. Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates Int. J. Biol. Macromol. 2012, 50 (4) 974-980
29. Wannachaiyasit, S.; Chanvorachote, P.; Nimmannit, U. A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats AAPS PharmSciTech 2008, 9 (3) 840-850
30. Wan, L.; Zhang, X.; Gunaseelan, S.; Pooyan, S.; Debrah, O.; Leibowitz, M. J.; Rabson, A. B.; Stein, S.; Sinko, P. J., Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects. AIDS Res. Ther. 2006, 3, (1).
31. Giammona, G.; Cavallaro, G.; Pitarresi, G. Studies of macromolecular prodrugs of zidovudine Adv. Drug Delivery Rev. 1999, 39 (1-3) 153-164
32. Gao, Y.; Katsuraya, K.; Kaneko, Y.; Mimura, T.; Nakashima, H.; Uryu, T. Synthesis of azidothymidine-bound Curdlan sulfate with anti-human immunodeficiency virus activity in vitro Polym. J. 1998, 30 (1) 31-36
33. Li, X.; Wu, Q.; Zhang, F.; Lin, X. F. Chemoenzymatic synthesis, characterization, and controlled release of functional polymeric prodrugs with acyclovir as pendant J. Appl. Polym. Sci. 2008, 108 (1) 431-437
34. Li, X.; Wu, Q.; Chen, Z.; Gong, X.; Lin, X. Preparation, characterization and controlled release of liver-targeting nanoparticles from the amphiphilic random copolymer Polymer 2008, 49 (22) 4769-4775
35. Neeraj, A.; Chandrasekar, M. J. N.; Sara, U. V. S.; Rohini, A. Poly(HEMA-zidovudine) conjugate: A macromolecular pro-drug for improvement in the biopharmaceutical properties of the drug Drug Delivery 2011, 18 (4) 272-280
36. Vlieghe, P.; Clerc, T.; Pannecouque, C.; Witvrouw, M.; De Clercq, E.; Salles, J. P.; Kraus, J. L. Synthesis of new covalently bound κ-carrageenan-AZT conjugates with improved anti-HIV activities J. Med. Chem. 2002, 45 (6) 1275-1283
37. Levy, G. A.; Adamson, G.; Phillips, M. J.; Scrocchi, L. A.; Fung, L.; Biessels, P.; Ng, N. F.; Ghanekar, A.; Rowe, A.; Ma, M. X. Z.; Levy, A.; Koscik, C.; He, W.; Gorczynski, R.; Brookes, S.; Woods, C.; McGilvray, I. D.; Bell, D. Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity Hepatology 2006, 43 (3) 581-591
38. Li, X.; Wu, Q.; Lu, M.; Zhang, F.; Lin, X. F. Novel hepatoma-targeting micelles based on chemo-enzymatic synthesis and self-assembly of galactose-functionalized ribavirin-containing amphiphilic random copolymer J. Polym. Sci., Polym. Chem. 2008, 46 (8) 2734-2744
39. Di Stefano, G.; Colonna, F. P.; Bongini, A.; Busi, C.; Mattioli, A.; Fiume, L. Ribavirin conjugated with lactosaminated poly- l -lysine. Selective delivery to the liver and increased antiviral activity in mice with viral hepatitis Biochem. Pharmacol. 1997, 54 (3) 357-363
40. Di Stefano, G.; Bignamini, A.; Busi, C.; Colonna, P. P.; Fiume, L. Enhanced accumulation of ribavirin and its metabolites in liver versus erythrocytes in mice administered with the liver targeted drug Italian J. Gastroenterol. Hepatol. 1997, 29 (5) 420-426
41. Kryger, M. B. L.; Smith, A. A. A.; Wohl, B. M.; Zelikin, A. N. Macromolecular prodrugs for controlled delivery of ribavirin. Macromol. Biosci. DOI: 10.1002/mabi.201300244.
42. Nair, B. Final report on the safety assessment of polyvinylpyrrolidone (PVP) Int. J. Toxicol. 1998, 17 (SUPPL. 4) 95-130
43. Kaneda, Y.; Tsutsumi, Y.; Yoshioka, Y.; Kamada, H.; Yamamoto, Y.; Kodaira, H.; Tsunoda, S.; Okamoto, T.; Mukai, Y.; Shibata, H.; Nakagawa, S.; Mayumi, T. The use of PVP as a polymeric carrier to improve the plasma half-life of drugs Biomaterials 2004, 25 (16) 3259-3266
44. Boyer, C.; Bulmus, V.; Davis, T. P.; Ladmiral, V.; Liu, J.; Perrier, S. b. Bioapplications of RAFT polymerization Chem. Rev. 2009, 109 (11) 5402-5436
45. Shimoni, O.; Postma, A.; Yan, Y.; Scott, A. M.; Heath, J. K.; Nice, E. C.; Zelikin, A. N.; Caruso, F. Macromolecule functionalization of disulfide-bonded polymer hydrogel capsules and cancer cell targeting ACS Nano 2012, 6 (2) 1463-1472
46. Zelikin, A. N.; Such, G. K.; Postma, A.; Caruso, F. Poly(vinylpyrrolidone) for bioconjugation and surface ligand immobilization Biomacromolecules 2007, 8 (9) 2950-2953
47. Moorcroft, M. J.; Davis, J.; Compton, R. G. Detection and determination of nitrate and nitrite: A review Talanta 2001, 54, 785-803
48. Kanuri, G.; Weber, S.; Volynets, V.; Spruss, A.; Bischoff, S. C.; Bergheim, I. Cinnamon extract protects against acute alcohol-induced liver steatosis in mice J. Nutr. 2009, 139 (3) 482-487
49. Markusic, D. M.; van Til, N. P.; Hiralall, J. K.; Elferink, R. P. J. O.; Seppen, J. Reduction of liver macrophage transduction by pseudotyping lentiviral vectors with a fusion envelope from Autographa californica GP64 and Sendai virus F2 domain BMC Biotechnol. 2009, 9
50. Tsubota, A.; Akuta, N.; Suzuki, F.; Suzuki, Y.; Someya, T.; Kobayashi, M.; Arase, Y.; Saitoh, S.; Ikeda, K.; Kumada, H. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load Intervirology 2002, 45, 33-42
51. Kmoníčková, E.; Potměšil, P.; Holý, A.; Zídek, Z. Purine P1 receptor-dependent immunostimulatory effects of antiviral acyclic analogues of adenine and 2,6-diaminopurine Eur. J. Pharmacol. 2006, 530 (1-2) 179-187
52. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Prodrugs: design and clinical applications Nat. Rev. Drug Discovery 2008, 7 (3) 255-270
53. Nielsen, A. L.; Steffensen, K.; Larsen, K. L. Self-assembling microparticles with controllable disruption properties based on cyclodextrin interactions Colloids Surf., B 2009, 73 (2) 267-275
54. Ren, S. D.; Chen, D. Y.; Jiang, M. Noncovalently connected micelles based on a β-cyclodextrin-containing polymer and adamantane end-capped poly(ε-caprolactone) via host-guest interactions J. Polym. Sci., Polym. Chem. 2009, 47 (17) 4267-4278
55. Zelikin, A. N.; Becker, A. L.; Johnston, A. P. R.; Wark, K. L.; Turatti, F.; Caruso, F. A general approach for DNA encapsulation in degradable polymer miocrocapsules ACS Nano 2007, 1 (1) 63-69
56. Pissuwan, D.; Boyer, C.; Gunasekaran, K.; Davis, T. P.; Bulmus, V. In vitro cytotoxicity of RAFT polymers Biomacromolecules 2010, 11 (2) 412-420
57. Chang, C.-W.; Bays, E.; Tao, L.; Alconcel, S. N. S.; Maynard, H. D. Differences in cytotoxicity of poly(PEGA)s synthesized by reversible addition-fragmentation chain transfer polymerization Chem. Commun. 2009, 24, 3580-3582
58. Moncada, S.; Palmer, R. M. J.; Higgs, E. A. Nitric oxide: Physiology, pathophysiology, and pharmacology Pharmacol. Rev. 1991, 43 (2) 109-142
59. Lavignac, N.; Nicholls, J. L.; Ferruti, P.; Duncan, R. Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker Macromol. Biosci. 2009, 9 (5) 480-487
60. Kovar, L.; Etrych, T.; Kabesova, M.; Subr, V.; Vetvicka, D.; Hovorka, O.; Strohalm, J.; Sklenar, J.; Chytil, P.; Ulbrich, K.; Rihova, B. Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells Tumor Biol. 2010, 31 (4) 233-242
61. Veronese, F. M.; Schiavon, O.; Pasut, G.; Mendichi, R.; Andersson, L.; Tsirk, A.; Ford, J.; Wu, G. F.; Kneller, S.; Davies, J.; Duncan, R. PEG-doxorubicin conjugates: Influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity Bioconjugate Chem. 2005, 16 (4) 775-784
62. Oberoi, H. S.; Laquer, F. C.; Marky, L. A.; Kabanov, A. V.; Bronich, T. K. Core cross-linked block ionomer micelles as pH-responsive carriers for cis -diamminedichloroplatinum(II) J. Controlled Release 2011, 153 (1) 64-72